Amarin Is Down but Not Out

The FDA denies Amarin's appeal.

Jan 21, 2014 at 10:31PM

Amarin's (NASDAQ:AMRN) decision from the Food and Drug Administration came a few days later than expected, but the result was as expected: The FDA turned down Amarin's appeal of the agency's decision to rescind its Special Protocol Assessment.

The division that reviewed the appeal was the same one that made the initial decision to rescind the SPA, so it's not surprising it would come to the same conclusion.

Upward and onward
Amarin plans to move the appeal up the chain of command. With each level taking 30 to 60 days to make a decision, it could take 10 months to reach the commissioner.

The SPA was supposed to allow Amarin to expand the indication for its triglyceride-lowering drug, Vascepa, to include patients with moderately high triglyceride levels as long as the biotech showed that Vascepa lowered triglycerides (it did) and that the company substantially enrolled an outcomes study (it has).

But the FDA rescinded the SPA after clinical trials run on AbbVie's (NYSE:ABBV) Tricor and Merck's (NYSE:MRK) Cordaptive lowered triglyceride levels but failed to show an effect on outcomes. Never mind that AbbVie's and Merck's drugs work under a different mechanism of action and tested a different set of patients than Amarin is trying to get approved for, the agency concluded that lowering triglycerides isn't a meaningful surrogate for reducing heart attacks and strokes.

Give us an expanded indication or else
Amarin's understanding is that the FDA won't take action on the application to expand the market until the appeal moves at least two levels higher, which should occur in late spring or early summer.

Interestingly, Amarin has given the FDA an ultimatum, telling the agency that it won't continue the REDUCE-IT outcomes study unless the FDA lives up to its side of the bargain and expands Vascepa's indication. "FDA is aware that if we don't get the ANCHOR indication that we are not going to be able to continue REDUCE-IT in its current form," John Thero, Amarin's president and CEO, told investors on the conference call.

I'm sympathetic to Amarin's dilemma. SPAs allow companies to run clinical trials with the confidence that they'll gain approval if things go as planned. But I'm not sure the FDA is going to be swayed into changing its mind because Amarin threatens to not follow through with its end of the deal after the FDA reaffirms its decision to back out. The agency wants to encourage innovation, but not at the expense of accurate calls on efficacy.

Moving on
Beyond trying to get the expanded indication, Amarin has a couple of backup plans. The FDA might let Amarin include the data from the trial of patients with moderately high triglyceride levels in the clinical-trials section of the package insert without technically being approved for that indication. Amarin might also try to argue it can tell doctors about the trial based on its First Amendment right of free speech.

Neither seems as good as a full approval, allowing Amarin to advertise the drug for the expanded indication, which is probably necessary to get Vascepa to blockbuster status.

Even without the expanded indication, Amarin thinks it has enough cash to become cash flow-positive selling Vascepa just to patients with extremely high triglyceride levels, although that likely includes modifying the outcomes study to reduce expenses.

Stay tuned; it's going to be an interesting year for Amarin.

A stock with potential in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Fool contributor Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information